再鼎醫藥-SB(09688.HK):則樂®(尼拉帕利)被納入中國國家醫保藥品目錄
格隆匯12月29日丨再鼎醫藥-SB(09688.HK)發佈公吿,則樂®(尼拉帕利)(則樂,是國家一類新藥,一種一天一次的口服聚(ADP-核糖)聚合酶(poly (ADP-ribose) polymerase)(“PARP”)抑制劑)已被納入中國國家醫療保障局最新發布的國家醫保藥品目錄,而公司已獲授權於中國大陸、中國香港和中國澳門上市推出則樂。則樂已被納入國家醫保目錄,用於複發性上皮性卵巢癌、輸卵管癌或原發性腹膜癌成人患者在含鉑化療達到完全緩解或部分緩解後的維持治療,亦是中國唯一獲批的無論患者生物標記物狀態如何,均能單藥用於一線和復發卵巢癌維持治療的PARP抑制劑。
卵巢癌是中國發病率最高的婦科腫瘤之一。儘管經過初始含鉑化療後得到緩解,但大多數卵巢癌患者都會無可避免地復發。而目前對於鉑敏感復發卵巢癌治療的選擇仍然非常有限。創新藥物可延長含鉑化療治療的緩解時間,延緩復發,造福中國的卵巢癌患者。
則樂為一種用於晚期及複發性上皮性卵巢癌、輸卵管癌或原發性腹膜癌成人患者對一線及二線含鉑化療達到完全緩解或部分緩解後的維持治療的單藥。根據最新的臨牀研究顯示,則樂作為用於一線鉑敏感的女性卵巢癌患者的單藥,能夠改善患者的無進展生存期,在總研究人羣中使疾病進展或死亡的風險降低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.